LRRK2 kinase activity regulates sphingolipid hydrolase enzymatic activities in different cell lines: induced pluripotent stem cell-derived dopaminergic neurons, primary monocyte‐derived macrophages and SH-SY5Y
Objective: To assess whether inhibition of the kinase activity of LRRK2 affects changes in enzyme activity of sphingolipid hydrolase in the culture of dopaminergic neurons…Use of concomitant medications before and after treatment with levodopa/carbidopa intestinal gel in patients with advanced Parkinson’s disease: summary of phase 3 and real-world studies
Objective: Evaluate the use of concomitant Parkinson’s disease (PD) medications before and after treatment with levodopa/carbidopa intestinal gel (LCIG) using data from phase 3 clinical…Hypoxia‑induced astrocyte activation and its protective effect on Parkinson’s disease
Objective: In this study, we aimed to investigate whether hypoxic conditions can activate cerebral astrocytes and explore their protective effects on α-synuclein pre-formed fibril (PFF)-treated…Improving inpatient medication management in hospitalized Parkinson’s patients
Objective: Develop a process for Parkinson's patients to provide individualized medication management to reduce length of stay,, mortality, 30-day readmissions, and increase patient satisfaction. Background:…Utilization pattern and factors associated with amantadine use in Parkinson’s disease (PD) of the French NS-Park cohort
Objective: To assess amantadine use in the French NS-Park cohort and factors associated with its prescription Background: Amantadine, a unique dopamine/glutamate drug, is approved worldwide…The effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial
Objective: To evaluating the effect of intranasal insulin administration on motor and non-motor symptoms in Parkinson’s disease patients; a randomized double-blinded placebo-controlled clinical trial Background:…Longitudinal change in clinical characteristics of LRRK2 carriers in a remote cohort
Objective: To examine change in clinical characteristics in LRRK2 G2019S carriers with Parkinson’s disease (PD) and without PD (non-manifest carriers) enrolled in Virtual Assessment of…Longitudinal brain volume decline in PD with RBD and olfactory dysfunction
Objective: To elucidate longitudinal brain atrophies in PD with or without RBD and anosmia at baseline. Background: REM sleep behavior disorder (RBD) and olfactory dysfunction…Benefits of Physician-Pharmacist Collaboration on Patient Outcomes in Parkinson’s Disease and Movement Disorders Clinic
Objective: To evaluate the impact of pharmacist participation in Parkinson’s disease and movement disorders clinic on the number of drug-related problems (DRPs), clinical outcomes, and…monogenic parkinson´s disease in a chilean cohort
Objective: To describe the minimum prevalence and distribution of monogenic forms of PD in a chilean cohort Background: About 3–5% of Parkinson’s disease (PD) patients…
- « Previous Page
- 1
- …
- 243
- 244
- 245
- 246
- 247
- …
- 436
- Next Page »